Alimera Sciences (ALIM) Getting Somewhat Positive Media Coverage, Report Shows
News stories about Alimera Sciences (NASDAQ:ALIM) have trended somewhat positive this week, according to Accern Sentiment Analysis. The research firm ranks the sentiment of media coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Alimera Sciences earned a daily sentiment score of 0.10 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 46.1006332926683 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
These are some of the news headlines that may have effected Accern Sentiment Analysis’s analysis:
- Alimera Sciences (ALIM) PT Set at $3.00 by HC Wainwright (americanbankingnews.com)
- Alimera Sciences (ALIM) Given Buy Rating at Cowen (americanbankingnews.com)
- Alimera posts quarterly net loss (healio.com)
- Alimera Sciences Inc (ALIM) Expected to Post Earnings of -$0.06 Per Share (americanbankingnews.com)
- Global Retinal Drugs and Biologics Market Report 2018 – Alimera Sciences, Janssen Biotech, F. Hoffmann-La Roche Ltd (sacramentotelescope.com)
A number of analysts recently issued reports on the company. HC Wainwright reiterated a “buy” rating and set a $3.00 price objective on shares of Alimera Sciences in a research note on Tuesday, June 12th. Zacks Investment Research upgraded Alimera Sciences from a “hold” rating to a “buy” rating and set a $1.00 price objective on the stock in a research note on Thursday, August 2nd. Cowen reiterated a “buy” rating and set a $3.00 price objective on shares of Alimera Sciences in a research note on Wednesday. ValuEngine upgraded Alimera Sciences from a “sell” rating to a “hold” rating in a research note on Friday, June 1st. Finally, B. Riley assumed coverage on Alimera Sciences in a research note on Friday, June 29th. They set a “buy” rating and a $2.75 price objective on the stock. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $2.44.
Alimera Sciences (NASDAQ:ALIM) last posted its earnings results on Monday, July 30th. The biopharmaceutical company reported ($0.06) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.06). The business had revenue of $10.92 million for the quarter, compared to analysts’ expectations of $10.78 million. research analysts anticipate that Alimera Sciences will post -0.27 earnings per share for the current year.
About Alimera Sciences
Alimera Sciences, Inc, a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. It focuses on diseases affecting the back of the eye or retina. The company offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness.
See Also: Technical Analysis
Receive News & Ratings for Alimera Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences and related companies with MarketBeat.com's FREE daily email newsletter.